French researchers have recently determined cannabis may protect against liver disease in patients diagnosed with hepatitis C virus (HCV) and human immunodeficiency virus (HIV). In the study, which was published in the Journal of Viral Hepatitis, a cohort of 838 HIV-HCV co-infected subjects were examined to determine if there was a link between cannabis use and steatosis (fatty liver disease). They concluded, “Daily cannabis use was independently associated with a reduced prevalence of steatosis” after adjusting for potential confounders. “Daily cannabis use may be a protective factor against steatosis in HIV-HCV co-infected patients.”
This information supports previous studies that have similarly determined cannabis may be beneficial for those infected with HIV/HCV. This information was originally published on the Daily Chronic, and has been approved by our Chief Medical Officer.